Le Lézard
Classified in: Health, Business
Subject: OFR

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering


JERSEY CITY, N.J., Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. ("60P"), (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its public offering of 5,260,901 units (the "Units") at a price to the public of $0.385 per Unit and 999,076 pre?funded units (the "Pre?Funded Units") at a price to the public of $0.375 per Pre?Funded Unit. The closing of the offering is expected to occur on or about January 31, 2024, subject to the satisfaction of customary closing conditions.

The underwriters have been granted an option, exercisable within 45 days after the closing of this offering, to purchase shares of 60P's common stock at a price of $0.385 per share and/or Warrants at a price of $0.01 per Warrant and/or Pre-Funded Warrants at a price of $0.375 per Pre-Funded Warrant, or any combination of additional shares of common stock, Warrants and/or Pre-Funded Warrants, representing, in the aggregate, up to 15% of the number of Units sold in this offering, 15% of the Warrants underlying the Units and Pre-Funded Units sold in this offering and 15% of the Pre-Funded Warrants underlying the Pre-Funded Units sold in this offering, in all cases less the underwriting discount to cover over-allotments, if any.

WallachBeth Capital is the Sole Bookrunner for the Offering

The offering is being conducted pursuant to 60P's registration statement on Form S?1 (File No. 333?276641) previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on January 24, 2024. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from WallachBeth Capital LLC, via email: [email protected], or by calling +1 (646) 237?8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

About WallachBeth Capital LLC

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. The firm's website is located at www.wallachbeth.com.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.     

Forward-Looking Statements

This press release may include forward-looking statements, including statements of future expectations regarding the business and offering of 60P's units. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. We undertake no obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

SOURCE WallachBeth Capital LLC


These press releases may also interest you

at 04:28
RaySearch will be showcasing its latest software innovations at ESTRO in Glasgow, May 3-6. Attendees will be able to book demonstrations of the treatment planning system RayStation®*, the oncology information system RayCare®*, and the cloud-based...

at 04:00
Forum will be held on May 30 at the Science Museum, LondonChaired by Professor Sir Munir Pirmohamed, Forum to consist of four panel sessions highlighting solutions to pressing issues facing private and public-sector innovators in the healthcare...

at 03:00
Clarivate Plc , a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligencetm solution, featuring a new post-approval variations module. The module for post-approval variations...

at 03:00
Varian, a Siemens Healthineers company, will showcase its ongoing commitment to embracing innovation and enhancing outcomes for cancer care teams and their patients at this year's 2024 European Society for Radiation Oncology (ESTRO) annual meeting,...

at 02:58
Today, 2 May 2024, is the last day of trading in unit rights in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million (the "Rights Issue"). The Rights Issue was resolved by the Board of...

at 02:34
SciBase Holding AB ("SciBase") (STO: SCIB), a pioneer in skin cancer detection and prevention, and prediction in dermatology, further deepens their commitment to patients and dermatologists during US Skin Cancer Awareness Month by highlighting the...



News published on and distributed by: